DeepMed Research

CUE-100 series

Generic Name: CUE-100 series

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Clinical Trials

CUE-102 in Recurrent Glioblastoma

Phase 1

Not yet recruiting

Conditions: Recurrent Glioblastoma
Glioblastoma
Glioma, Malignant

Interventions: Biological: CUE-102

First Posted Date: 2025-04-09

Last Posted Date: 2025-04-09

Lead Sponsor: David Reardon, MD

Target Recruit Count: 18

Registration Number: NCT06917885

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Phase 1

Completed

Conditions: Pancreatic Cancer
Colorectal Cancer
Gastric Cancer
Ovarian Cancer

Interventions: Drug: CUE-102

First Posted Date: 2022-05-04

Last Posted Date: 2025-03-18

Lead Sponsor: Cue Biopharma

Target Recruit Count: 42

Registration Number: NCT05360680

Locations: 🇺🇸
Stanford Advanced Medicine Cancer Center, Palo Alto, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

and more 12 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy